Madrid, Spain and Heidelberg, Germany, February 18, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed a non-exclusive distribution agreement for its proprietary TruePrime™ Single Cell WGA Kit with D-MARK BIOSCIENCES for the North American market.
Under the terms of the agreement, SYGNIS grants D-MARK BIOSCIENCES the non-exclusive rights to promote, market and sell TruePrime™ Single Cell WGA Kit to scientists working in the wide field of molecular biology in Canada. TruePrime™ Single Cell WGA Kit is the first in a row of products of SYGNIS’ TruePrime™ product family based on the combination of the recently discovered DNA primase “TthPrimPol” and the Phi29 polymerase which allows the amplification of total genomic DNA from single cells without the need of random synthetic primers.
D-MARK BIOSCIENCES is a specialized provider offering a broad portfolio of innovative research reagents as well as state-of-the-art instruments in the wide field of molecular biology including next generation sequencing and gene silencing applications to customers all over Canada.
“We are very pleased about this distribution agreement for our proprietary product with D-MARK BIOSCIENCES, an important door opener to North America. With its wide customer network focused on molecular biology, D-MARK BIOSCIENCES is best positioned to significantly expand our market reach and make our product available in Canada,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “After rolling out TruePrime™ Single Cell WGA Kit in Europe, North America is the next logical step and a further milestone in our product and commercialization strategy. The high interest in our product we are experiencing encourages us in our efforts to further expand our distribution channels to leverage the benefits of this new technology to researchers working in NGS throughout the world.”
About TruePrime™
TruePrime™ is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS’ portfolio. TruePrime™ is based on the combination of the recently discovered DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
The resulting benefits of this innovative approach are enormous and include complete absence of common artifacts linked to the use of oligonucleotides, a reduced amplification bias in genome coverage compared to methods using random synthetic primers, a surpassing reliability as contaminating DNA is not amplified and an exquisite reproducibility when DNA is amplified from single mammalian cells. Moreover, TruePrime™ shows superior sensitivity, is easy to use and works perfectly well with all commonly used NGS platforms such as Illumina and Ion Torrent.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi ® , licensed to an industry leading partner and is currently developing its own TruePrime™ product line based on its proprietary TruePrime™ technology for use in the fast growing field of Next Generation Sequencing. The first product for single cell DNA amplification was launched in January 2015.
###
Disclaimer
This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###
Help employers find you! Check out all the jobs and post your resume.
